Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General meeting (AGM) today elected Annette Clancy to Sobi’s Board of Directors. Ms. Clancy has over 30 years of experience in the Pharmaceutical and Biotechnology Industry, working in a variety of roles in the US and UK. With Ms Clancy, Sobi’s Board expands to eight members with international experience in a wide variety of relevant healthcare disciplines.
“I am delighted to welcome Annette to Sobi”, said Bo Jesper Hansen, Chairman of the Board at Sobi. “Annette's extensive experience from a variety of senior R & D, commercial, and business development functions in the pharmaceutical industry makes her a perfect addition to the Board. Annette's skills, knowledge and experience will be invaluable to furthering the success of Sobi.”
Annette Clancy was born 1954 and has a BSc Hons Pharmacology, from Bath University UK. She is Chairman as well as Non-Executive Director of the Board in Genable Technologies and ObsEva SA. Ms. Clancy was Head of Transactions and Alliance Management at GlaxoSmithKline (GSK) where she was responsible for executing major transactions ranging from early drug discovery partnerships, to global commercial alliances and Mergers and Acquisitions. Since her retirement from GSK in 2008, Ms. Clancy has been appointed as Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-2013).
Ms. Clancy also currently serves as Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides strategic advice on both new and existing investments. Annette Clancy does not hold any shares or options in Sobi. She is independent in relation to the company and its management and in relation to the company´s principal shareholders.
The ordinary Board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were re-elected and Bo Jesper Hansen was re-elected chairman of the Board.
The information was released for public distribution on May 8, 2014 at 18:30 CET.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.
For more information please contact
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135